The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13

Publication date: 9 May 2017
Source:Vaccine, Volume 35, Issue 20
Author(s): Salah Zangenah, Linda Björkhem-Bergman, Anna-Carin Norlin, Susanne Hansen, Lars Lindqvist, Birgitta Henriques-Normark, Peter Bergman
BackgroundPatients with IgG-deficiency often suffer from repeated bacterial infections with S. pneumoniae. Since there is a lack of knowledge regarding whether IgG-deficient patients would benefit from conjugate pneumococcal vaccination, we set out to evaluate the effect of Prevnar13 vaccination in IgG1- and/or IgG2-deficient patients.MethodWe designed a small pilot-study including IgG1- and/or IgG2-deficient patients (n=10) and age- and sex-matched healthy controls (n=10). Serum, plasma and heparin-blood were collected prior to vaccination, as well as 1, 2 and 4weeks post vaccination, and the levels of opsonophagocytic activity (Opa) titers and anti-pneumococcal IgG-antibodies were analyzed.ResultsPatients generally had lower Opa-titers than controls for most serotypes, but they exhibited an almost normal vaccine response to serotypes 6A and 6B. Notably, 5/10 patients showed vaccine-response to at least one serotype. Most patients reached the presumably protective levels of Opa-titers ≥8 and anti-pneumococcal IgG levels of 0.35µg/ml by 4weeks post-vaccination for a majority of the serotypes.ConclusionOur results show that vaccination of IgG-deficient patients with Prevnar13 is likely to have a clinical benefit. Our initial findings will provide a framework for future vaccine-trials in this vulnerable patient group.Registered at http://ift.tt/PmpYKN as NCT01847781.



http://ift.tt/2pOcSLV